The RDHL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the RDHL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The RDHL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View RDHL Detailed Price Forecast - CNN Money||View RDHL Detailed Summary - Google Finance|
|View RDHL Detailed Summary - Yahoo! Finance||View RDHL Stock Research & Analysis - Zacks.com|
|View RDHL Trends & Analysis - Trade-Ideas||View RDHL Major Holders - Barrons|
|View RDHL Call Transcripts - NASDAQ||View RDHL Breaking News & Analysis - Seeking Alpha|
|View RDHL Annual Report - CompanySpotlight.com||View RDHL OTC Short Report - OTCShortReport.com|
|View RDHL Fundamentals - TradeKing||View RDHL SEC Filings - Bar Chart|
|View Historical Prices for RDHL - The WSJ||View Performance/Total Return for RDHL - Morningstar|
|View the Analyst Estimates for RDHL - MarketWatch||View the Earnings History for RDHL - CNBC|
|View the RDHL Earnings - StockMarketWatch||View RDHL Buy or Sell Recommendations - MacroAxis|
|View the RDHL Bullish Patterns - American Bulls||View RDHL Short Pain Metrics - ShortPainBot.com|
|View RDHL Stock Mentions - StockTwits||View RDHL Stock Mentions - PennyStockTweets|
|View RDHL Stock Mentions - Twitter||View RDHL Investment Forum News - Investor Hub|
|View RDHL Stock Mentions - Yahoo! Message Board||View RDHL Stock Mentions - Seeking Alpha|
|View Insider Transactions for RDHL - SECform4.com||View Insider Transactions for RDHL - Insider Cow|
|View RDHL Major Holdings Summary - CNBC||View Insider Disclosure for RDHL - OTC Markets|
|View Insider Transactions for RDHL - Yahoo! Finance||View Institutional Holdings for RDHL - NASDAQ|
|View RDHL Stock Insight & Charts - FinViz.com||View RDHL Investment Charts - StockCharts.com|
|View RDHL Stock Overview & Charts - BarChart||View RDHL User Generated Charts - Trading View|
RedHill Gets Two New Patents for Crohn's Disease Candidate
Posted on Thursday July 05, 2018
RedHill Biopharma (RDHL) announces allowances of two new patents from the United States Patent and Trademark Office and the European Patent Office for its Crohn's disease candidate, RHB-104.
RedHill Biopharma (RDHL) Catches Eye: Stock Jumps 5.4%
Posted on Monday July 02, 2018
RedHill Biopharma (RDHL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
RedHill Biopharma Announces Allowance of Two New RHB-104 Patents Ahead of Top-Line Phase III Results for Crohn’s Disease
Posted on Monday July 02, 2018
TEL-AVIV, Israel and RALEIGH, N.C., July 02, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal (GI) diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) and an Intention to Grant from the European Patent Office (EPO) for two new patents covering RHB-104, expected to be valid until at least February 5, 2029, once granted. The development of RHB-104 for Crohn’s disease is based on the hypothesis that Crohn’s disease is caused by Mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients.
SAN FRANCISCO, CA / ACCESSWIRE / June 28, 2018 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc. (JAGX) (Jaguar), today announced that it has entered into an agreement (the Agreement) with RedHill Biopharma Ltd. (RedHill) (RDHL), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, to establish a U.S. co-promotion program for Mytesi® (crofelemer 125 mg delayed-release tablets), Napo's FDA-approved drug, for the current approved indication. Mytesi is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).